William Lewis Sells 18,750 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00. Following the transaction, the chief executive officer now owns 379,534 shares of the company’s stock, valued at $29,580,879.96. This trade represents a 4.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

William Lewis also recently made the following trade(s):

• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Price Performance

Shares of INSM opened at $80.78 on Friday. The company has a market capitalization of $14.45 billion, a price-to-earnings ratio of -14.55 and a beta of 1.11. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $82.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The business’s 50-day moving average is $72.69 and its 200-day moving average is $73.04.

Institutional Investors Weigh In On Insmed

A number of large investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC boosted its position in shares of Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after acquiring an additional 4,560 shares during the period. Capital CS Group LLC acquired a new stake in Insmed in the fourth quarter worth about $586,000. Orion Portfolio Solutions LLC boosted its holdings in Insmed by 48.5% during the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after buying an additional 9,170 shares during the last quarter. Ally Bridge Group NY LLC lifted its holdings in shares of Insmed by 16.9% during the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after purchasing an additional 21,833 shares in the last quarter. Finally, Vestal Point Capital LP raised its position in Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after buying an additional 850,000 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently commented on INSM shares. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Truist Financial reissued a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, Morgan Stanley raised their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $84.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.